Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Shareholder Meeting (November 2015)
11 slides from Proteomics International Laboratories's shareholder meeting presentation, Nov 20, 2015
Slide 1: Annual General Meeting Shareholder Presentation
For personal use only Shareholder Presentation | Perth, WA Annual General Meeting | 20th November 2015 Global leader & innovator in the field of proteomics ASX: PIQ 1 Proteomics International Laboratories Ltd
Slide 2: Disclaimer & forward-looking statements
Disclaimer & forward-looking statements For personal use only This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 3: 2015 - an exciting year!
2015 - an exciting year! For personal use only Corporate – Listed @ 20 cents (April) – Options listed @ 1 cent (October) Analytical services – Major contracts in food QC testing and biosimilars (April) – WA Exporter of the Year Award [Healthcare] (September) Diagnostics – Ground breaking predictive
Slide 4: Corporate overview
Corporate overview For personal use only Capital Structure Shareholders ASX code PIQ Top 20 Shareholders 69% Shares on issue 50.6m Major Shareholders Listed (@20c) 16th April 2015 Richard Lipscombe 31.9% XYLO Pty Ltd 12.4% Market capitalisation (@36.5c) $18.4m John Dunlop 7.5% 4 month price range 21
Slide 5: The history of PIQ
The history of PIQ For personal use only Revenue generating Company – Established 2001 Global leader & innovator in field of proteomics World’s first company to receive ISO 17025 laboratory accreditation for proteomics services Proven technology with established IP Operates from purpose built, state
Slide 6: Business model
Business model For personal use only Three synergistic business units Unifying platform technology - leverage & efficiency Existing revenue generation & deal flow - multiple major upside opportunities 6 Proteomics International Laboratories Ltd
Slide 7: Highlights: Diagnostics
Highlights: Diagnostics For personal use only Predictive test for diagnosis of diabetic kidney disease International Diabetes Foundation estimates 387 million people globally have diabetes According to US Centre for Disease Control, 35% of adults with diabetes have chronic kidney disease and 20% wil
Slide 8: Highlights: Analytical services
Highlights: Analytical services For personal use only Proven track record in analysing protein drugs – Blue chip, global client base with 50% export income (priced in USD) – Analytical & consulting services income in 2015 grew 27% year on year – Major contracts post listing: a2 Milk Company (quality
Slide 9: Why PIQ?
Why PIQ? For personal use only Leveraged business model – Established income reduces burn – Analytics division underpins cash flow Strong IP position – Patents granting in major jurisdictions for ground-breaking PromarkerD diagnostic Proven technology platform – Proof of concept established with mul
Slide 10: Please contact
Please contact For personal use only Richard Lipscombe Managing Director T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com www.proteomicsinternational.com Terry Sweet Chairman E: t.sweet@proteomicsinternational.com Greg Wood Financial Advisor, K S Capital M: +61 416 076 377 | E: g.wood@k
Slide 11: For personal use only
For personal use only 11 Proteomics International Laboratories Ltd
Proteomics International Laboratories — Shareholder Meeting (November 2015) on 6ix